![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Vol. 63, Issue 3, 653-658, March 2003
Department of Pharmacology, Yale University School of Medicine, New
Haven, Connecticut
Dopamine transporter (DAT) is a major target of cocaine, one of the
most abused drugs. Major efforts have been focused on defining residues
in DAT involved in cocaine binding. We have isolated the
Drosophila melanogaster DAT (dDAT) cDNA, which is 10-fold less sensitive to cocaine than the mammalian DATs. Replacing transmembrane domain 2 (TM2) of mouse DAT (mDAT) with dDAT sequence reduced cocaine sensitivity. The reciprocal construct exhibited increased cocaine sensitivity. Switching residue 105 in TM2, a phenylalanine conserved in all mammalian DATs, to methionine, the
corresponding residue in dDAT, resulted in a functional transporter with cocaine sensitivity 4-fold lower. Replacing F105 with alanine, leucine, isoleucine, serine, threonine, asparagine, or glutamine resulted in transporters with low transport activity. In contrast, changing F105 to the other aromatic residues tyrosine or tryptophan retained more than 75% transport activity and high cocaine
sensitivity. Most significantly, the reciprocal construct, switching
the methionine in dDAT at the corresponding residue to phenylalanine,
increased cocaine sensitivity 3-fold. Finally, the mDAT mutant with a
cysteine at this position had normal transport activity but exhibited
cocaine sensitivity that was 15-fold lower. These results suggest that F105 in mDAT contributes to high-affinity cocaine binding. The functional cocaine-insensitive mutants provide tools for the study of
the mechanism of cocaine addiction.
This article has been cited by other articles:
|
|
 |
|
  B. Guptaroy, M. Zhang, E. Bowton, F. Binda, L. Shi, H. Weinstein, A. Galli, J. A. Javitch, R. R. Neubig, and M. E. Gnegy A Juxtamembrane Mutation in the N Terminus of the Dopamine Transporter Induces Preference for an Inward-Facing Conformation Mol. Pharmacol., March 1, 2009; 75(3): 514 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Beuming, L. Shi, J. A. Javitch, and H. Weinstein A Comprehensive Structure-Based Alignment of Prokaryotic and Eukaryotic Neurotransmitter/Na+ Symporters (NSS) Aids in the Use of the LeuT Structure to Probe NSS Structure and Function Mol. Pharmacol., November 1, 2006; 70(5): 1630 - 1642. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Chen, M. R. Tilley, H. Wei, F. Zhou, F.-M. Zhou, S. Ching, N. Quan, R. L. Stephens, E. R. Hill, T. Nottoli, et al. Abolished cocaine reward in mice with a cocaine-insensitive dopamine transporter PNAS, June 13, 2006; 103(24): 9333 - 9338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Melamed and B. I. Kanner Transmembrane Domains I and II of the {gamma}-Aminobutyric Acid Transporter GAT-4 Contain Molecular Determinants of Substrate Specificity Mol. Pharmacol., June 1, 2004; 65(6): 1452 - 1461. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Sato, Y.-W. Zhang, A. Androutsellis-Theotokis, and G. Rudnick Analysis of Transmembrane Domain 2 of Rat Serotonin Transporter by Cysteine Scanning Mutagenesis J. Biol. Chem., May 28, 2004; 279(22): 22926 - 22933. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Loland, C. Granas, J. A. Javitch, and U. Gether Identification of Intracellular Residues in the Dopamine Transporter Critical for Regulation of Transporter Conformation and Cocaine Binding J. Biol. Chem., January 30, 2004; 279(5): 3228 - 3238. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
